ACT-1239 is under clinical development by Artificial Cell Technologies and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ACT-1239’s likelihood of approval (LoA) and phase transition for Malaria took place on 03 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACT-1239 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ACT-1239 overview

ACT-1239 is under development for the prevention of malaria. The therapeutic candidate incorporates T1BT epitopes from the circumsporozoite (CS) protein of the sporozoite stage of Plasmodium falciparum. It is administered through intramuscular route. It is developed based on ultra-thin multilayer polypeptide nano-film technology naming electrostatic layer-by-layer (LBL) self-assembly.

Artificial Cell Technologies overview

Artificial Cell Technologies (ACT) is a synthetic vaccine manufACTurer. The company produces and offers vaccines for respiratory syncytial virus and falciparum malaria disorders. It uses multilayer polypeptide nanofilm based technology platform for developing and producing synthetic vaccines. ACT’s vaccines are produced by electrostatic layer-by-layer deposition of poly amino acids onto a calcium carbonate core. The company’s vaccines are produced in a transportable, aseptic closed-loop and computer controlled manufACTuring device, which can be housed in a portable and self-contained cleanroom. It also partners with academic and government organizations. ACT is headquartered in New Haven, Connecticut, the US.

Quick View ACT-1239 LOA Data

Report Segments
  • Innovator
Drug Name
  • ACT-1239
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.